Pyrotinib plus Xeloda in HER2+ metastatic breast cancer
Breast Cancer – Pyrotinib/Xeloda beats Tykerb/Xeloda
Background Pyrotinib is an innovative cancer drug targeting EGFR, HER2, and HER4 which are components expressed on cell surface. Pyrotinib plus Xeloda has shown meaningful benefits and acceptable side effects…